Skip to main content
English
Català
Čeština
Deutsch
Español
Français
Gàidhlig
Italiano
Latviešu
Magyar
Nederlands
Polski
Português
Português do Brasil
Srpski (lat)
Suomi
Svenska
Türkçe
Tiếng Việt
Қазақ
বাংলা
हिंदी
Ελληνικά
Српски
Yкраї́нська
Log In
Email address
Password
Log in
New user? Click here to register.
Have you forgotten your password?
Communities & Collections
All of DSpace
Statistics
English
Català
Čeština
Deutsch
Español
Français
Gàidhlig
Italiano
Latviešu
Magyar
Nederlands
Polski
Português
Português do Brasil
Srpski (lat)
Suomi
Svenska
Türkçe
Tiếng Việt
Қазақ
বাংলা
हिंदी
Ελληνικά
Српски
Yкраї́нська
Log In
Email address
Password
Log in
New user? Click here to register.
Have you forgotten your password?
Home
AL SHIFA COLLEGE OF PHARMACY
RESOURCES-ACP
ARTICLES
Articles-Health Sciences(ACP)
Assessing Post-Marketing Requirements for Orphan Drugs: A Cross-Sectional Analysis of FDA and EMA Oversight : Clinical Pharmacology and Therapeutics
Assessing Post-Marketing Requirements for Orphan Drugs: A Cross-Sectional Analysis of FDA and EMA Oversight : Clinical Pharmacology and Therapeutics
Loading...
Files
Clin Pharma and Therapeutics - 2024 - Yu - Assessing Post‐Marketing Requirements for Orphan Drugs A Cross‐Sectional.pdf
(1.44 MB)
Date
2024-09-03
Authors
Jae Hyeon Yu1,† , Sangwon Lee 2,3,† , Yoon Jung Kim 1, Won Young Kim 1, Min Jung Lee 1 and Yun Kim 1, *
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Abstract
Description
Keywords
Citation
URI
http://98.70.32.231:4000/handle/123456789/1339
Collections
Articles-Health Sciences(ACP)
Full item page